Global Burden of Disease Health Financing Collaborator Network; (2019) Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050. Lancet (London, England), 393 (10187). pp. 2233-2260. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(19)30841-4

GBD 2017 DALYs and HALE Collaborators; (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392 (10159). pp. 1859-1922. ISSN 0140-6736 DOI: https://doi.org/10.1016/s0140-6736(18)32335-3

GBD 2017 DALYs and HALE Collaborators; (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392 (10159). pp. 1859-1922. ISSN 1474-547X DOI: https://doi.org/10.1016/S0140-6736(18)32335-3

Halliday, Brian P; Wassall, Rebecca; Lota, Amrit S; Khalique, Zohya; Gregson, John; Newsome, Simon; Jackson, Robert; Rahneva, Tsveta; Wage, Rick; Smith, Gillian; +16 more... Venneri, Lucia; Tayal, Upasana; Auger, Dominique; Midwinter, William; Whiffin, Nicola; Rajani, Ronak; Dungu, Jason N; Pantazis, Antonis; Cook, Stuart A; Ware, James S; Baksi, A John; Pennell, Dudley J; Rosen, Stuart D; Cowie, Martin R; Cleland, John GF; Prasad, Sanjay K; (2018) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet (London, England). ISSN 0140-6736 DOI: https://doi.org/10.1016/s0140-6736(18)32484-x

West African Network for Clinical Trials of Antimalarial Drugs (; (2018) Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet (London, England), 391 (10128). pp. 1378-1390. ISSN 0140-6736 DOI: https://doi.org/10.1016/s0140-6736(18)30291-5